Spyre Therapeutics, Inc (SYRE) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Spyre Therapeutics, Inc. (SYRE) has completed a Phase 1 trial called “A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of SPY001-001 in Healthy Participants.” The study aims to test basic safety and drug behavior in the body, a key first step before moving SPY001-001 into patient trials.
The main treatment in this study is SPY001-001, an experimental drug given as single and multiple doses to healthy volunteers. The goal is to see how well people tolerate the drug and how their bodies process it, compared with a placebo that has no active medicine.
The study is interventional, meaning participants were assigned to receive either SPY001-001 or placebo under controlled conditions. It used random assignment, a stepwise dose-escalation model, and a double-blind setup where participants and all study staff did not know who received the drug, with a focus on understanding basic safety and dosing.
The trial was first submitted on June 3, 2024, signaling the start of Spyre’s first-in-human work with SPY001-001. The overall status is now “Completed,” and the record was most recently updated on March 17, 2026, showing that top-line safety work is done even though detailed results are not yet posted.
For investors, completion of this Phase 1 study reduces early development risk for SYRE and can support future announcements on dose selection and Phase 2 plans. Sentiment may improve if Spyre signals clean safety data, especially versus peers developing early-stage biologics and inflammation drugs, though lack of posted results means reaction may stay cautious for now.
Spyre’s progress in this first-in-human program may help it compete for attention among small-cap biotech names, but any share price move will likely depend on future disclosures on safety, exposure levels, and next-step indications. This study is now completed and recently updated, with further details available on the ClinicalTrials.gov portal.
To learn more about SYRE’s potential, visit the Spyre Therapeutics, Inc drug pipeline page.